TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Status:
Completed
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
Both TCH (docetaxel/carboplatin/trastuzumab) and EC followed by
TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) regimens as Neoadjuvant
Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is
unknown which regimen is better. This study is to evaluate the efficacy and safety of TCH
(docetaxel/carboplatin/trastuzumab) and EC followed by TH(epirubicin/cyclophosphamide
followed by docetaxe plus trastuzumab) regimens as Neoadjuvant Treatment in HER2-Positive
breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for
survival. Safety and tolerability assessed by number of grade 4 toxicities and
hospitalizations.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital